A first of its kind study from Harvard Medical School and Massachusetts General Hospital shows that the supplement that S-Adenosyl Methionine (SAMe), can be an effective support for patients with major depressive disorders who do not respond to their antidepressant medication. According to the investigators, led by George I. Papakostas, MD, of the Center for Treatment-Resistant Depression at Massachusetts General Hospital and Harvard Medical School in Boston, SAM-e treats depression. During the study, significantly more SAMe-treated than placebo-treated patients experienced a clinical response on the 17-item Hamilton Depression Rating Scale (HAM-D), which was the primary study outcome. Remission rates were also higher with SAMe than with placebo.
“With each study we continue to gain a better understanding of SAM-e’s role in treating depression. This new finding, albeit preliminary and in urgent need of replication, suggests significant, clinically meaningful differences in outcome among patients who had SAM-e added to their antidepressant medication treatment compared to those taking a placebo with their medication.”
George I. Papakostas, M.D.
George I. Papakostas is Associate Professor of Psychiatry at Harvard Medical School and Director of Treatment-Resistant Depression Studies in the Department of Psychiatry at Massachusetts General Hospital in Boston, Massachusetts. The focus of Dr Papakostas’ research includes the pharmacotherapy of major depressive disorder including treatment-resistant depression, the study of the “placebo” effect and it’s relevance to clinical trial design in major depressive disorder, and the study of clinical and biologic predictors, moderators, and mediators of treatment outcome in major depressive disorder. Dr Papakostas has received numerous national and international research awards from sources including the American College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologium, the New Clinical Drug Evaluation Unit of the National Institute of Mental Health, the American Psychiatric Association, the World Federation of Societies of Biological Psychiatry, the American Academy of Clinical Psychiatrists, the International College of Psychosomatic Medicine, and the American Foundation for Suicide Prevention. He is author or co-author of over 150 clinical and scientific publications and book chapters, and is author of the book entitled: “Pharmacotherapy for Depression” (In Press- World Scientific Publishing and Imperial College Press). His publications have appeared in prominent journals, including the American Journal of Psychiatry, Biological Psychiatry, the Journal of Clinical Psychiatry, and the Journal of Clinical Psychopharmacology. He is also on the editorial board of the journal “Psychiatry Research”, and also field editor for Psychopharmacology for the “World Journal of Biological Psychiatry”. Dr. Papakostas is often invited throughout the United States and abroad to lecture on a wide range topics pertaining to the treatment of depression. To date, he has delivered more than 100 lectures at National or International meetings in more than 30 countries. Dr. Papakostas attended Medical School at the New York University School of Medicine. He completed his residency in adult Psychiatry at Massachusetts General Hospital and McLean Hospital, and a fellowship in Clinical Neuropsychopharmacology at Massachusetts General Hospital that was funded by the American College of Neuropsychopharmacology.
Dr. Papakostas attended Medical School at the New York University School of Medicine. He completed his residency in adult Psychiatry at Massachusetts General Hospital and McLean Hospital, and a fellowship in Clinical Neuropsychopharmacology at Massachusetts General Hospital that was funded by the American College of Neuropsychopharmacology.
For Liver Support, Depression and Arthritis
Classified as a prescription drug in Germany, Russia, Italy, and Spain, SAMe has been the subject of studies on depression at Harvard Medical School, the University of California, and King’s College Hospital in London. What these studies have shown is that SAMe influences brain chemicals by helping to convert the feel-good neurotransmitters norepinephrine into epinephrine, and serotonin into melatonin. It is also involved in the formation of myelin, the white sheath that surrounds nerve cells. It can improve brain-cell membrane fluidity.
But there is so much more to know about SAMe than its mood enhancing effects. Click on the links below and read all about what it does for osteoarthritis and liver disease as well.